CKD Venture Capital Corporation
VC Fund
Seoul, South Korea
CKD Venture Capital Corporation is a Seoul, Korea-based venture capital firm. Founded in 1997, CKD Venture Capital Corporation considers seed, early stage, late stage and mezzanine investments.
- Total investments:
- 29
- Last investment:
- Lead investor:
- 7%
Last updated:
For AI agents: llms.txt
Industries CKD Venture Capital Corporation invests in
Stages CKD Venture Capital Corporation invests in
Countries CKD Venture Capital Corporation invests in
Round sizes
Round size
- Seed
- $1.7M–$3M
- Series A
- $3.3M–$10M
- Series B
- $497k–$18M
Investment Focus
Industry
- Biotechnology 10 (34%)
- Health Care 7 (24%)
- Therapeutics 7 (24%)
- Pharmaceutical 4 (14%)
- Information Technology 4 (14%)
Stage
- Series A 13 (45%)
- Series B 7 (24%)
- Seed 4 (14%)
- Series C 2 (7%)
- Series D 1 (3%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Cenyx Biotech
|
Cenyx Biotech develops diagnostic and therapeutic nano-compounds formed based on nanozymes and nanoparticles. | $8.2M / Series B / Mar 31, 2026 | |
1st Biotherapeutics
|
1STBIO is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success. 1STBIO currently has 24 employees with expertise in biochemistry, medicinal chemistry,pharmacology, and business development. We are working as a core expertise team of drug discovery/development and are rigorously connected to R&D networking of academia, hospitals, industry, CRO’s and investors in Korea, China and US. Our ultimate goal is to use our experience and knowledge to discover and develop effective molecular therapeutics for patients. | $21.9M / Series D / Jan 26, 2026 | |
Portrai
|
Portrai is a biotechnology research company utilizing AI in spatial transcriptomics to improve biopsy quality. The company specializes in developing highly accurate artificial intelligence technology to analyze spatial transcriptomics results. This enables doctors to efficiently examine a patient's illness by analyzing tissue samples withprecision. | $9.9M / Series B / Dec 02, 2025 | |
Qunova Computing, Inc.
|
Quantum computing based computing innovations for new materials and drug discovery, and advanced technology solution consulting services. | $10M / Series A / Aug 18, 2025 | |
ROBOS
|
Robos is a hybrid robot system built by evaluating biological object vision data using Lidar Vision and Open CV-based Object Detection. By combining self-developed biomaterial machine vision technology and robot technology, it intends to expand into a company that delivers core services to diverse industrial sites such as manufacturing, food, andmedical. | $18.2M / Series B / Jun 18, 2025 | |
Pin Therapeutics
|
Pin Therapeutics is founded in Feb 2017, fast growing stage with member composition of 25% in USA and 75% in Korea. Drug discovery leaderships are from global pharma and biotech companies along with talented scientists both in Korea and USA.* Active Focus - PinE3: E3 ligase screening cascade for identifying novel warheads - PinGLUE: Assaycascade for molecular glue degrader screening* Programs - Selective Molecular Glue Degrader (CK1α) - Molecular Glue Degrader Programs (5-6 Undisclosed) - PROTAC Program (1 Undisclosed) | $13.6M / Series C / Dec 27, 2024 | |
|
ROBOS
|
Robos is a hybrid robot system built by evaluating biological object vision data using Lidar Vision and Open CV-based Object Detection. By combining self-developed biomaterial machine vision technology and robot technology, it intends to expand into a company that delivers core services to diverse industrial sites such as manufacturing, food, andmedical. | $5.2M / Series A / Feb 13, 2024 | |
Medinno
|
Medinno develops cell therapeutics for brain diseases. The company's therapy uses technology to treat a wide range of diseases, including hypoxic-ischemic encephalopathy, neonatal refractory brain diseases, and severe intraventricular hemorrhages.. | $8.2M / Series C / Oct 16, 2023 | |
Cellemedy
|
Cellemedy is a biotechnology company committed to developing next-generation therapeutic proteins aimed at replacing conventional antibody treatments. Their proprietary platform offers enhanced antigen-binding capabilities and broader applicability compared to traditional antibodies. Its mission is to advance human health by creating innovativebiopharmaceuticals that improve treatment outcomes across various medical conditions. | $7.4M / Series A / Oct 04, 2023 | |
Zymedi
|
Zymedi is a pharmaceutical company that develops drugs for life-threatening diseases. | $12.1M / Series A / May 30, 2023 | |
| See all 29 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does CKD Venture Capital Corporation invest in?
CKD Venture Capital Corporation invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 29 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is CKD Venture Capital Corporation's check size?
CKD Venture Capital Corporation typically joins rounds of $1.7M–$3M at Seed, $3.3M–$10M at Series A and $497k–$18M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds CKD Venture Capital Corporation participates in.
When did CKD Venture Capital Corporation last invest?
The most recent investment recorded for CKD Venture Capital Corporation closed in Mar 2026. Shizune tracks 29 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
